Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ.

Nat Metab. 2019 Apr;1(4):460-474. doi: 10.1038/s42255-019-0052-9. Epub 2019 Apr 8.

2.

Reliability of ultrashort electrocardiographic indices in hypertension: the quest for a clinically applicable prognostic marker.

Politi K, Kaminer K, Nussinovitch U.

J Investig Med. 2019 Aug 16. pii: jim-2019-001106. doi: 10.1136/jim-2019-001106. [Epub ahead of print]

PMID:
31420365
3.

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I.

J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. Review.

4.

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K.

J Immunother Cancer. 2019 Jul 10;7(1):172. doi: 10.1186/s40425-019-0643-8.

5.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

6.

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.

Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K.

Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10.

PMID:
31182434
7.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

8.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.

Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K.

Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.

9.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
10.

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX.

Cell Rep. 2019 Apr 23;27(4):1277-1292.e7. doi: 10.1016/j.celrep.2019.03.085.

11.

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS.

Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Review.

PMID:
30824587
12.

Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo.

Dermentzaki G, Politi KA, Lu L, Mishra V, Pérez-Torres EJ, Sosunov AA, McKhann GM 2nd, Lotti F, Shneider NA, Przedborski S.

eNeuro. 2019 Feb 19;6(1). pii: ENEURO.0308-18.2018. doi: 10.1523/ENEURO.0308-18.2018. eCollection 2019 Jan-Feb.

13.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.

Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA.

Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8.

14.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

15.

ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.

Wilson FH, Politi K.

Cancer Discov. 2018 Jun;8(6):676-678. doi: 10.1158/2159-8290.CD-18-0368.

16.

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.

Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV.

Nat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23.

17.

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS.

J Thorac Oncol. 2018 Jun;13(6):831-839. doi: 10.1016/j.jtho.2018.03.008. Epub 2018 Mar 22.

18.

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA.

Clin Cancer Res. 2018 Apr 15;24(8):1872-1880. doi: 10.1158/1078-0432.CCR-17-1341. Epub 2018 Jan 12.

19.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

20.

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.

Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR.

Biomed Res Int. 2017;2017:7694202. doi: 10.1155/2017/7694202. Epub 2017 Oct 8.

21.

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K.

Cancer Discov. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12.

22.

Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.

Politi K, Wajapeyee N.

Cold Spring Harb Protoc. 2017 Sep 1;2017(9):pdb.top097550. doi: 10.1101/pdb.top097550.

PMID:
28864574
23.

[ANTI-N-METHYL-D-ASPARTATE (NMDA) ENCEPHALITIS: THE ISRAELI PEDIATRIC MULTI-CENTER EXPERIENCE].

Politi K, Marom D, Ashkenazi S, Livni G, Goldberg H, Shuper A, Steinberg T, Lahat E, Haiman E, Shtrausberg R.

Harefuah. 2017 Aug;156(8):478-481. Hebrew.

PMID:
28853520
24.

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR.

Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19.

25.

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.

McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, Jacks T, Varmus H.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417. Epub 2016 Oct 4.

26.

Axonal Degeneration: RIPK1 Multitasking in ALS.

Politi K, Przedborski S.

Curr Biol. 2016 Oct 24;26(20):R932-R934. doi: 10.1016/j.cub.2016.08.052.

27.

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Gettinger S, Politi K.

Clin Cancer Res. 2016 Sep 15;22(18):4539-41. doi: 10.1158/1078-0432.CCR-16-1401. Epub 2016 Jul 28.

28.

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N.

Cell Rep. 2016 Jul 12;16(2):457-471. doi: 10.1016/j.celrep.2016.05.087. Epub 2016 Jun 23.

29.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.

Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, Goldberg SB, Pao W, Politi K.

Clin Cancer Res. 2016 Jan 15;22(2):426-35. doi: 10.1158/1078-0432.CCR-15-0620. Epub 2015 Sep 4.

30.

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.

Crisci I, Aragona M, Politi KS, Daniele G, Del Prato S.

Acta Diabetol. 2015 Dec;52(6):1129-33. doi: 10.1007/s00592-015-0800-6. Epub 2015 Aug 21.

PMID:
26293127
31.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Morgensztern D, Politi K, Herbst RS.

JAMA Oncol. 2015 May;1(2):146-8. doi: 10.1001/jamaoncol.2014.278. No abstract available.

PMID:
26181013
32.

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Ayeni D, Politi K, Goldberg SB.

Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13.

33.

The Regulatory Machinery of Neurodegeneration in In Vitro Models of Amyotrophic Lateral Sclerosis.

Ikiz B, Alvarez MJ, Ré DB, Le Verche V, Politi K, Lotti F, Phani S, Pradhan R, Yu C, Croft GF, Jacquier A, Henderson CE, Califano A, Przedborski S.

Cell Rep. 2015 Jul 14;12(2):335-45. doi: 10.1016/j.celrep.2015.06.019. Epub 2015 Jul 2.

34.

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

Politi K, Ayeni D, Lynch T.

Cancer Cell. 2015 Jun 8;27(6):751-3. doi: 10.1016/j.ccell.2015.05.012.

35.

Lung cancer in the era of precision medicine.

Politi K, Herbst RS.

Clin Cancer Res. 2015 May 15;21(10):2213-20. doi: 10.1158/1078-0432.CCR-14-2748.

36.

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.

Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, Zhang X, Webster JD, Ritt D, Ghosal S, Hoschuetzky H, Simpson RM, Biswas R, Politi K, Morrison DK, Varmus HE, Guha U.

Cancer Discov. 2015 May;5(5):534-49. doi: 10.1158/2159-8290.CD-14-0750. Epub 2015 Mar 3.

37.

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.

Song X, Fan PD, Bantikassegn A, Guha U, Threadgill DW, Varmus H, Politi K.

Cancer Res. 2015 Mar 15;75(6):1035-45. doi: 10.1158/0008-5472.CAN-13-1625. Epub 2015 Jan 16.

38.

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W.

Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.

39.

Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas.

Bantikassegn A, Song X, Politi K.

Am J Respir Cell Mol Biol. 2015 Apr;52(4):409-17. doi: 10.1165/rcmb.2014-0312MA.

40.

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

Politi K, Gettinger S.

Clin Cancer Res. 2014 Nov 15;20(22):5576-8. doi: 10.1158/1078-0432.CCR-14-2306. Epub 2014 Sep 16.

41.

Testing models of the APC tumor suppressor/β-catenin interaction reshapes our view of the destruction complex in Wnt signaling.

Yamulla RJ, Kane EG, Moody AE, Politi KA, Lock NE, Foley AV, Roberts DM.

Genetics. 2014 Aug;197(4):1285-302. doi: 10.1534/genetics.114.166496. Epub 2014 Jun 14.

42.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

43.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.

Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17.

44.

Necroptosis drives motor neuron death in models of both sporadic and familial ALS.

Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, Ikiz B, Hoffmann L, Koolen M, Nagata T, Papadimitriou D, Nagy P, Mitsumoto H, Kariya S, Wichterle H, Henderson CE, Przedborski S.

Neuron. 2014 Mar 5;81(5):1001-1008. doi: 10.1016/j.neuron.2014.01.011. Epub 2014 Feb 6.

45.

MYCxing it up with FGFR1 in squamous cell lung cancer.

Lockwood W, Politi K.

Cancer Discov. 2014 Feb;4(2):152-4. doi: 10.1158/2159-8290.CD-13-1049.

46.

Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse.

Pirazzoli V, Politi K.

Cold Spring Harb Protoc. 2014 Feb 1;2014(2):178-81. doi: 10.1101/pdb.prot077842.

PMID:
24492774
47.

Translational therapeutics in genetically engineered mouse models of cancer.

Olive KP, Politi K.

Cold Spring Harb Protoc. 2014 Feb 1;2014(2):131-43. doi: 10.1101/pdb.top069997.

PMID:
24492770
48.

De novo selection of oncogenes.

Chacón KM, Petti LM, Scheideman EH, Pirazzoli V, Politi K, DiMaio D.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E6-E14. doi: 10.1073/pnas.1315298111. Epub 2013 Dec 16.

49.

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Berger AH, Chen M, Morotti A, Janas JA, Niki M, Bronson RT, Taylor BS, Ladanyi M, Van Aelst L, Politi K, Varmus HE, Pandolfi PP.

PLoS One. 2013 Nov 8;8(11):e79526. doi: 10.1371/journal.pone.0079526. eCollection 2013.

50.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.

Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W.

Genome Res. 2013 Sep;23(9):1434-45. doi: 10.1101/gr.152322.112. Epub 2013 Jun 3.

Supplemental Content

Loading ...
Support Center